Phosphoinositide 3-Kinases

Handbook of Cell Signaling, Second Edition

Volumn 2, Issue , 2009, Pages 1049-1060

  Fruman, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882898183     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374145-5.00132-7     Document Type: Chapter

References (130)

1. DA Fruman, RE Meyers and LC Cantley (1998) Phosphoinositide kinases. Annu Rev Biochem 67 481-507.
2. B Vanhaesebroeck, SJ Leevers, K Ahmadi, J Timms, R Katso, PC Driscoll, R Woscholski, PJ Parker and MD Waterfield (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70 535-602.
3. C Jimenez, C Hernandez, B Pimentel and AC Carrera (2002) The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. J Biol Chem 277 41,556-41,562.
4. P Rodriguez-Viciana, PH Warne, R Dhand, B Vanhaesebroeck, I Gout, MJ Fry, MD Waterfield and J Downward (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 527-532.
5. S Gupta, AR Ramjaun, P Haiko, Y Wang, PH Warne, B Nicke, E Nye, G Stamp, K Alitalo and J Downward (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129 957-968.
6. CM Taniguchi, JO Aleman, K Ueki, J Luo, T Asano, H Kaneto, G Stephanopoulos, LC Cantley and CR Kahn (2007) The p85alpha regulatory subunit of phosphoinositide 3-kinase potentiates c-Jun N-terminal kinase-mediated insulin resistance. Mol Cell Biol 27 2830-2840.
7. Andrews S, Stephens LR, Hawkins PT. PI3K class IB pathway. Sci STKE 2007 2007;cm2.
8. S Suire, AM Condliffe, GJ Ferguson, CD Ellson, H Guillou, K Davidson, H Welch, J Coadwell, M Turner, ER Chilvers, PT Hawkins and L Stephens (2006) Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat Cell Biol 8 1303-1309.
9. E Patrucco, A Notte, L Barberis, G Selvetella, A Maffei, M Brancaccio, S Marengo, G Russo, O Azzolino, SD Rybalkin, L Silengo, F Altruda, R Wetzker, MP Wymann, G Lembo and E Hirsch (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118 375-387.
10. E Ciraolo, M Iezzi, R Marone, S Marengo, C Curcio, C Costa, O Azzolino, C Gonella, C Rubinetto, H Wu, W Dastru, EL Martin, L Silengo, F Altruda, E Turco, L Lanzetti, P Musiani, T Ruckle, C Rommel, JM Backer, G Forni, MP Wymann and E Hirsch (2008) Phosphoinositide 3-kinase p110β activity: key role in metabolism and mammary gland cancer but not development. Sci Signaling 1 ra3.
11. J Guillermet-Guibert, K Bjorklof, A Salpekar, C Gonella, F Ramadani, A Bilancio, S Meek, AJ Smith, K Okkenhaug and B Vanhaesebroeck (2008) The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 105 8292-8297.
12. S Jia, Z Liu, S Zhang, P Liu, L Zhang, SH Lee, J Zhang, S Signoretti, M Loda, TM Roberts and JJ Zhao (2008) Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454 776-779.
13. CH Huang, D Mandelker, O Schmidt-Kittler, Y Samuels, VE Velculescu, KW Kinzler, B Vogelstein, SB Gabelli and LM Amzel (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318 1744-1748.
14. N Miled, Y Yan, WC Hon, O Perisic, M Zvelebil, Y Inbar, D Schneidman-Duhovny, HJ Wolfson, JM Backer and RL Williams (2007) Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317 239-242.
15. EH Walker, O Perisic, C Ried, L Stephens and RL Williams (1999) Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature 402 313-320.
16. ZA Knight, B Gonzalez, ME Feldman, ER Zunder, DD Goldenberg, O Williams, R Loewith, D Stokoe, A Balla, B Toth, T Balla, WA Weiss, RL Williams and KM Shokat (2006) A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125 733-747.
17. ME Pacold, S Suire, O Perisic, S Lara-Gonzalez, CT Davis, EH Walker, PT Hawkins, L Stephens, JF Eccleston and RL Williams (2000) Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103 931-943.
18. EH Walker, ME Pacold, O Perisic, L Stephens, PT Hawkins, MP Wymann and RL Williams (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6 909-919.
19. M Falasca, WE Hughes, V Dominguez, G Sala, F Fostira, MQ Fang, R Cazzolli, PR Shepherd, DE James and T Maffucci (2007) The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem 282 28,226-28,236.
20. M Falasca and T Maffucci (2007) Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans 35 211-214.
21. HC Birkeland and H Stenmark (2004) Protein targeting to endosomes and phagosomes via FYVE and PX domains. Curr Top Microbiol Immunol 282 89-115.
22. JM Backer (2008) The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem J 410 1-17.
23. KF Tolias and LC Cantley (1999) Pathways for phosphoinositide synthesis. Chem Phys Lipids 98 69-77.
24. DJ Gillooly, IC Morrow, M Lindsay, R Gould, NJ Bryant, JM Gaullier, RG Parton and H Stenmark (2000) Localization of phosphatidylinositol 3-phosphate in yeast and mammalian cells. EMBO J 19 4577-4588.
25. RH Michell, VL Heath, MA Lemmon and SK Dove (2006) Phosphatidylinositol 3, 5-bisphosphate: metabolism and cellular functions. Trends Biochem Sci 31 52-63.
26. A Shisheva (2008) PIKfyve: partners, significance, debates and paradoxes. Cell Biol Intl 32 591-604.
27. LR Rohrschneider, JF Fuller, I Wolf, Y Liu and DM Lucas (2000) Structure, function, and biology of SHIP proteins. Genes Dev 14 505-520.
28. FL Robinson and JE Dixon (2006) Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol 16 403-412.
29. KM Ferguson, JM Kavran, VG Sankaran, E Fournier, SJ Isakoff, EY Skolnik and MA Lemmon (2000) Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. Mol Cell 6 373-384.
30. MA Lemmon (2008) Membrane recognition by phospholipid-binding domains. Nat Rev Mol Cell Biol 9 99-111.
31. SE Lietzke, S Bose, T Cronin, J Klarlund, A Chawla, MP Czech and DG Lambright (2000) Structural basis of 3-phosphoinositide recognition by pleckstrin homology domains. Mol Cell 6 385-394.
32. J Bravo, D Karathanassis, CM Pacold, ME Pacold, CD Ellson, KE Anderson, PJ Butler, I Lavenir, O Perisic, PT Hawkins, L Stephens and RL Williams (2001) The crystal structure of the PX domain from p40(phox) bound to phosphatidylinositol 3-phosphate. Mol Cell 8 829-839.
33. K Saito, L Tautz and T Mustelin (2007) The lipid-binding SEC14 domain. Biochim Biophys Acta 1771 719-726.
34. PE Stromhaug, F Reggiori, J Guan, CW Wang and DJ Klionsky (2004) Atg21 is a phosphoinositide binding protein required for efficient lipidation and localization of Atg8 during uptake of aminopeptidase I by selective autophagy. Mol Biol Cell 15 3553-3566.
35. P Varnai and T Balla (2006) Live cell imaging of phosphoinositide dynamics with fluorescent protein domains. Biochim Biophys Acta 1761 957-967.
36. GJ Ferguson, L Milne, S Kulkarni, T Sasaki, S Walker, S Andrews, T Crabbe, P Finan, G Jones, S Jackson, M Camps, C Rommel, M Wymann, E Hirsch, P Hawkins and L Stephens (2007) PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol 9 86-91.
37. F Garcon, DT Patton, JL Emery, E Hirsch, R Rottapel, T Sasaki and K Okkenhaug (2008) CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood 111 1464-1471.
38. M Nishio, K Watanabe, J Sasaki, C Taya, S Takasuga, R Iizuka, T Balla, M Yamazaki, H Watanabe, R Itoh, S Kuroda, Y Horie, I Forster, TW Mak, H Yonekawa, JM Penninger, Y Kanaho, A Suzuki and T Sasaki (2007) Control of cell polarity and motility by the PtdIns(3, 4, 5)P3 phosphatase SHIP1. Nat Cell Biol 9 36-44.
39. JA Deane and DA Fruman (2004) Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu Rev Immunol 22 563-598.
40. K Okkenhaug, K Ali and B Vanhaesebroeck (2007) Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol 28 80-87.
41. AC Donahue and DA Fruman (2004) PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol 15 183-197.
42. DA Fruman, SB Snapper, CM Yballe, L Davidson, JY Yu, FW Alt and LC Cantley (1999) Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. Science 283 393-397.
43. H Suzuki, Y Terauchi, M Fujiwara, S Aizawa, Y Yazaki, T Kadowaki and S Koyasu (1999) Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. Science 283 390-392.
44. L Stephens, C Ellson and P Hawkins (2002) Roles of PI3Ks in leukocyte chemotaxis and phagocytosis. Curr Opin Cell Biol 14 203-213.
45. K Hill, S Krugmann, SR Andrews, WJ Coadwell, P Finan, HC Welch, PT Hawkins and LR Stephens (2005) Regulation of P-Rex1 by phosphatidylinositol (3, 4, 5)-trisphosphate and Gbetagamma subunits. J Biol Chem 280 4166-4173.
46. P Storz and A Toker (2002) 3'-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. Front Biosci 7 d886-d902.
47. B Dummler and BA Hemmings (2007) Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 35 231-235.
48. BD Manning and LC Cantley (2007) AKT/PKB signaling: navigating downstream. Cell 129 1261-1274.
49. DR Calnan and A Brunet (2008) The FoxO code. Oncogene 27 2276-2288.
50. DA Guertin and DM Sabatini (2007) Defining the role of mTOR in cancer. Cancer Cell 12 9-22.
51. PT Bhaskar and N Hay (2007) The two TORCs and Akt. Dev Cell 12 487-502.
52. S Wullschleger, R Loewith and MN Hall (2006) TOR signaling in growth and metabolism. Cell 124 471-484.
53. L Bozulic, B Surucu, D Hynx and BA Hemmings (2008) PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 30 203-213.
54. HW Chang, M Aoki, D Fruman, KR Auger, A Bellacosa, PN Tsichlis, LC Cantley, TM Roberts and PK Vogt (1997) Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276 1848-1850.
55. LR Borlado, C Redondo, B Alvarez, C Jimenez, LM Criado, J Flores, MA Marcos, AC Martinez, D Balomenos and AC Carrera (2000) Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation inI vivo. Faseb J 14 895-903.
56. C Jimenez, DR Jones, P Rodriguez-Viciana, A Gonzalez-Garcia, E Leonardo, S Wennstrom, C von Kobbe, JL Toran, RB L, V Calvo, SG Copin, JP Albar, ML Gaspar, E Diez, MA Marcos, J Downward, AC Martinez, I Merida and AC Carrera (1998) Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17 743-753.
57. A Di Cristofano, P Kotsi, YF Peng, C Cordon-Cardo, KB Elkon and PP Pandolfi (1999) Impaired Fas response and autoimmunity in Pten+/− mice. Science 285 2122-2125.
58. K Podsypanina, LH Ellenson, A Nemes, J Gu, M Tamura, KM Yamada, C Cordon-Cardo, G Catoretti, PE Fisher and R Parsons (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96 1563-1568.
59. A Suzuki, MT Yamaguchi, T Ohteki, T Sasaki, T Kaisho, Y Kimura, R Yoshida, A Wakeham, T Higuchi, M Fukumoto, T Tsubata, PS Ohashi, S Koyasu, JM Penninger, T Nakano and TW Mak (2001) T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14 523-534.
60. A Bellacosa, JR Testa, SP Staal and PN Tsichlis (1991) A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254 274-277.
61. JH Paik, R Kollipara, G Chu, H Ji, Y Xiao, Z Ding, L Miao, Z Tothova, JW Horner, DR Carrasco, S Jiang, DG Gilliland, L Chin, WH Wong, DH Castrillon and RA DePinho (2007) FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128 309-323.
62. JJ Zhao, H Cheng, S Jia, L Wang, OV Gjoerup, A Mikami and TM Roberts (2006) The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci USA 103 16,296-16,300.
63. MG Kharas, JA Deane, S Wong, KR O’Bosky, N Rosenberg, ON Witte and DA Fruman (2004) Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood 103 4268-4275.
64. MG Kharas, MR Janes, VM Scarfone, MB Lilly, ZA Knight, KM Shokat and DA Fruman (2008) Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 118 3038-3050.
65. T Fukao, T Yamada, M Tanabe, Y Terauchi, T Ota, T Takayama, T Asano, T Takeuchi, T Kadowaki, J Hata Ji and S Koyasu (2002) Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat Immunol 3 295-304.
66. JA Deane, MG Kharas, JS Oak, LN Stiles, J Luo, TI Moore, H Ji, C Rommel, LC Cantley, TE Lane and DA Fruman (2007) T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling. Blood 109 2894-2902.
67. DA Fruman (2007) The role of class I phosphoinositide 3-kinase in T-cell function and autoimmunity. Biochem Soc Trans 35 177-180.
68. K Okkenhaug, A Bilancio, G Farjot, H Priddle, S Sancho, E Peskett, W Pearce, SE Meek, A Salpekar, MD Waterfield, AJ Smith and B Vanhaesebroeck (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 1031-1034.
69. JS Oak and DA Fruman (2007) Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity 40 433-441.
70. DJ Rossi and IL Weissman (2006) Pten, tumorigenesis, and stem cell self-renewal. Cell 125 229-231.
71. MJ Welham, MP Storm, E Kingham and HK Bone (2007) Phosphoinositide 3-kinases and regulation of embryonic stem cell fate. Biochem Soc Trans 35 225-228.
72. OH Yilmaz, R Valdez, BK Theisen, W Guo, DO Ferguson, H Wu and SJ Morrison (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 475-482.
73. Z Tothova, R Kollipara, BJ Huntly, BH Lee, DH Castrillon, DE Cullen, EP McDowell, S Lazo-Kallanian, IR Williams, C Sears, SA Armstrong, E Passegue, RA DePinho and DG Gilliland (2007) FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128 325-339.
74. M Groszer, R Erickson, DD Scripture-Adams, R Lesche, A Trumpp, JA Zack, HI Kornblum, X Liu and H Wu (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294 2186-2189.
75. C Kenyon (2001) A conserved regulatory system for aging. Cell 105 165-168.
76. S Clement, U Krause, F Desmedt, JF Tanti, J Behrends, X Pesesse, T Sasaki, J Penninger, M Doherty, W Malaisse, JE Dumont, Y Le Marchand-Brustel, C Erneux, L Hue and S Schurmans (2001) The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409 92-97.
77. LC Foukas, M Claret, W Pearce, K Okkenhaug, S Meek, E Peskett, S Sancho, AJ Smith, DJ Withers and B Vanhaesebroeck (2006) Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 366-370.
78. DN Gross, AP van den Heuvel and MJ Birnbaum (2008) The role of FoxO in the regulation of metabolism. Oncogene 27 2320-2336.
79. D Chen, F Mauvais-Jarvis, M Bluher, SJ Fisher, A Jozsi, LJ Goodyear, K Ueki and CR Kahn (2004) p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol Cell Biol 24 320-329.
80. DA Fruman, F Mauvais-Jarvis, DA Pollard, CM Yballe, D Brazil, RT Bronson, CR Kahn and LC Cantley (2000) Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat Genet 26 379-382.
81. F Mauvais-Jarvis, K Ueki, DA Fruman, MF Hirshman, K Sakamoto, LJ Goodyear, M Iannacone, D Accili, LC Cantley and CR Kahn (2002) Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J Clin Invest 109 141-149.
82. Y Terauchi, Y Tsuji, S Satoh, H Minoura, K Murakami, A Okuno, K Inukai, T Asano, Y Kaburagi, K Ueki, H Nakajima, T Hanafusa, Y Matsuzawa, H Sekihara, Y Yin, JC Barrett, H Oda, T Ishikawa, Y Akanuma, I Komuro, M Suzuki, K Yamamura, T Kodama, H Suzuki, K Yamamura, T Kodama, H Suzuki, S Koyasu, S Aizawa, K Tobe, Y Fukui, Y Yazaki and T Kadowaki (1999) Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet 21 230-235.
83. K Ueki, CM Yballe, SM Brachmann, D Vicent, JM Watt, CR Kahn and LC Cantley (2002) Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci USA 99 419-424.
84. K Ueki, DA Fruman, SM Brachmann, YH Tseng, LC Cantley and CR Kahn (2002) Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 22 965-977.
85. B Geering, PR Cutillas, G Nock, SI Gharbi and B Vanhaesebroeck (2007) Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci USA 104 7809-7814.
86. CM Taniguchi, TT Tran, T Kondo, J Luo, K Ueki, LC Cantley and CR Kahn (2006) Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN. Proc Natl Acad Sci USA 103 12, 093-12, 097.
87. K Ueki, DA Fruman, CM Yballe, M Fasshauer, J Klein, T Asano, LC Cantley and CR Kahn (2003) Positive and negative roles of p85 alpha and p85 beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. J Biol Chem 278 48,453-48,466.
88. J Luo, SJ Field, JY Lee, JA Engelman and LC Cantley (2005) The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170 455-464.
89. J Luo, CL Sobkiw, MF Hirshman, MN Logsdon, TQ Li, LJ Goodyear and LC Cantley (2006) Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab 3 355-366.
90. CM Taniguchi, T Kondo, M Sajan, J Luo, R Bronson, T Asano, R Farese, LC Cantley and CR Kahn (2006) Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab 3 343-353.
91. D Weinkove and SJ Leevers (2000) The genetic control of organ growth: insights from Drosophila. Curr Op Genet Dev 10 75-80.
92. TP Neufeld (2004) Genetic analysis of TOR signaling in Drosophila. Curr Top Microbiol Immunol 279 139-152.
93. J Luo, JR McMullen, CL Sobkiw, L Zhang, AL Dorfman, MC Sherwood, MN Logsdon, JW Horner, RA Depinho, S Izumo and LC Cantley (2005) Class IA Phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 25 9491-9502.
94. T Shioi, PM Kang, PS Douglas, J Hampe, CM Yballe, J Lawitts, LC Cantley and S Izumo (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19 2537-2548.
95. T Shioi, JR McMullen, PM Kang, PS Douglas, T Obata, TF Franke, LC Cantley and S Izumo (2002) Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22 2799-2809.
96. AL Edinger (2007) Controlling cell growth and survival through regulated nutrient transporter expression. Biochem J 406 1-12.
97. T Maehama and JE Dixon (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 273 13,375-13,378.
98. S Gustafson, KM Zbuk, C Scacheri and C Eng (2007) Cowden syndrome. Semin Oncol 34 428-434.
99. M Cully, H You, AJ Levine and TW Mak (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6 184-192.
100. I Vivanco and CL Sawyers (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 489-501.
101. AG Bader, S Kang, L Zhao and PK Vogt (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5 921-929.
102. Y Samuels and K Ericson (2006) Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18 77-82.
103. AG Bader, S Kang and PK Vogt (2006) Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103 1475-1479.
104. M Gymnopoulos, MA Elsliger and PK Vogt (2007) Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104 5569-5574.
105. SJ Isakoff, JA Engelman, HY Irie, J Luo, SM Brachmann, RV Pearline, LC Cantley and JS Brugge (2005) Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 65 10,992-11,000.
106. Y Samuels, LA Diaz Jr, O Schmidt-Kittler, JM Cummins, L Delong, I Cheong, C Rago, DL Huso, C Lengauer, KW Kinzler, B Vogelstein and VE Velculescu (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7 561-573.
107. Network, T. C. G. A. R (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 1061-1068.
108. DW Parsons Jr, S Jones, X Zhang, JC Lin, RJ Leary, P Angenendt, P Mankoo, H Carter, IM Siu, GL Gallia, A Olivi, R McLendon, BA Rasheed, S Keir, T Nikolskaya, Y Nikolsky, DA Busam, H Tekleab, LA Diaz, J Hartigan, DR Smith, RL Strausberg, SK Marie, SM Shinjo, H Yan, GJ Riggins, DD Bigner, R Karchin, N Papadopoulos, G Parmigiani, B Vogelstein, VE Velculescu and KW Kinzler (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321 1807-1812.
109. AJ Philp, IG Campbell, C Leet, E Vincan, SP Rockman, RH Whitehead, RJ Thomas and WA Phillips (2001) The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61 7426-7429.
110. MG Kharas and DA Fruman (2005) ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65 2047-2053.
111. JD Carpten, AL Faber, C Horn, GP Donoho, SL Briggs, CM Robbins, G Hostetter, S Boguslawski, TY Moses, S Savage, M Uhlik, A Lin, J Du, YW Qian, DJ Zeckner, G Tucker-Kellogg, J Touchman, K Patel, S Mousses, M Bittner, R Schevitz, MH Lai, KL Blanchard and JE Thomas (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 439-444.
112. C Rommel, M Camps and H Ji (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7 191-201.
113. DF Barber, A Bartolome, C Hernandez, JM Flores, C Fernandez-Arias, L Rodriguez-Borlado, E Hirsch, M Wymann, D Balomenos and AC Carrera (2006) Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol 176 589-593.
114. DF Barber, A Bartolome, C Hernandez, JM Flores, C Redondo, C Fernandez-Arias, M Camps, T Ruckle, MK Schwarz, S Rodriguez, AC Martinez, D Balomenos, C Rommel and AC Carrera (2005) PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11 933-935.
115. M Camps, T Ruckle, H Ji, V Ardissone, F Rintelen, J Shaw, C Ferrandi, C Chabert, C Gillieron, B Francon, T Martin, D Gretener, D Perrin, D Leroy, PA Vitte, E Hirsch, MP Wymann, R Cirillo, MK Schwarz and C Rommel (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11 936-943.
116. K Ali, A Bilancio, M Thomas, W Pearce, AM Gilfillan, C Tkaczyk, N Kuehn, A Gray, J Giddings, E Peskett, R Fox, I Bruce, C Walker, C Sawyer, K Okkenhaug, P Finan and B Vanhaesebroeck (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431 1007-1011.
117. AM Condliffe, K Davidson, KE Anderson, CD Ellson, T Crabbe, K Okkenhaug, B Vanhaesebroeck, M Turner, L Webb, MP Wymann, E Hirsch, T Ruckle, M Camps, C Rommel, SP Jackson, ER Chilvers, LR Stephens and PT Hawkins (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 1432-1440.
118. M Laffargue, R Calvez, P Finan, A Trifilieff, M Barbier, F Altruda, E Hirsch and MP Wymann (2002) Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16 441-451.
119. W Swat, V Montgrain, TA Doggett, J Douangpanya, K Puri, W Vermi and TG Diacovo (2006) Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 107 2415-2422.
120. LM Webb, E Vigorito, MP Wymann, E Hirsch and M Turner (2005) Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 175 2783-2787.
121. JS Oak, MP Matheu, I Parker, MD Cahalan and DA Fruman (2007) Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. Biochem Soc Trans 35 1109-1113.
122. MP Matheu, JA Deane, I Parker, DA Fruman and MD Cahalan (2007) Class IA phosphoinositide 3-kinase modulates basal lymphocyte motility in the lymph node. J Immunol 179 2261-2269.
123. A Bilancio, K Okkenhaug, M Camps, JL Emery, T Ruckle, C Rommel and B Vanhaesebroeck (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107 642-650.
124. T Ruckle, MK Schwarz and C Rommel (2006) PI3Kgamma inhibition: towards an “aspirin of the 21st century”? Nat Rev Drug Discov 5 903-918.
125. P Workman, PA Clarke, S Guillard and FI Raynaud (2006) Drugging the PI3 kinome. Nat Biotech 24 794-796.
126. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008.
127. SM Maira, F Stauffer, J Brueggen, P Furet, C Schnell, C Fritsch, S Brachmann, P Chene, A De Pover, K Schoemaker, D Fabbro, D Gabriel, M Simonen, L Murphy, P Finan, W Sellers and C Garcia-Echeverria (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7 1851-1863.
128. C Garcia-Echeverria and WR Sellers (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27 5511-5526.
129. P Voigt, C Brock, B Nurnberg and M Schaefer (2005) Assigning functional domains within the p101 regulatory subunit of phosphoinositide 3-kinase gamma. J Biol Chem 280 5121-5127.
130. SC Shekar, H Wu, Z Fu, SC Yip, Nagajyothi, SM Cahill, ME Girvin and JM Backer (2005) Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 280 27,850-27,855.